The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Screening for breast cancer with mammography
Abstract
BACKGROUND: A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. OBJECTIVES: To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH STRATEGY: We searched PubMed (November 2008). SELECTION CRITERIA: Randomised trials comparing mammographic screening with no mammographic screening. DATA COLLECTION AND ANALYSIS: Both authors independently extracted data. Study authors were contacted for additional information. MAIN RESULTS: Eight eligible trials were identified. We excluded a biased trial and included 600,000 women in the analyses. Three trials with adequate randomisation did not show a significant reduction in breast cancer mortality at 13 years (relative risk (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02); four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality with an RR of 0.75 (95% CI 0.67 to 0.83). The RR for all seven trials combined was 0.81 (95% CI 0.74 to 0.87). We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. The trials with adequate randomisation did not find an effect of screening on cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).Numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42) for the two adequately randomised trials that measured this outcome; the use of radiotherapy was similarly increased. AUTHORS' CONCLUSIONS: Screening is likely to reduce breast cancer mortality. As the effect was lowest in the adequately randomised trials, a reasonable estimate is a 15% reduction corresponding to an absolute risk reduction of 0.05%. Screening led to 30% overdiagnosis and overtreatment, or an absolute risk increase of 0.5%. This means that for every 2000 women invited for screening throughout 10 years, one will have her life prolonged and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress for many months because of false positive findings. It is thus not clear whether screening does more good than harm. To help ensure that the women are fully informed of both benefits and harms before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today
Doll, R., & Peto, R. (1981) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/66.6.1192 · Cited by 3,927
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY
Tabár, L., Gad, A., Holmberg, L. H., Ljungquist, U., Fagerberg, C. J. G., Baldetorp, L., Gröntoft, O., Lundström, B., Månson, J. C., Eklund, G., et al. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92204-4 · Cited by 1,781
Long-term effects of mammography screening: updated overview of the Swedish randomised trials
Nyström, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjöld, B., & Rutqvist, L. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08020-0 · Cited by 1,183
Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force
Humphrey, L. L., Helfand, M., Chan, B. K. S., & Woolf, S. H. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_1-200209030-00012 · Cited by 1,137
Efficacy of screening mammography. A meta-analysis
Kerlikowske, K. M. (1995) · JAMA · doi:10.1001/jama.273.2.149 · Cited by 1,131
Boyd, N. F., Byng, J. W., Jong, R. A., Fishell, E. K., Little, L. E., Miller, A. B., Lockwood, G. A., Tritchler, D. L., & Yaffe, M. J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.9.670 · Cited by 1,105
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,053
Cited by
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
The benefits and harms of breast cancer screening: an independent review
(2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,492
Screening, T. I. U. P. O. B. C., Marmot, M. G., Altman, D. G., Cameron, D. A., Dewar, J. A., Thompson, S. G., & Wilcox, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.177 · Cited by 1,069
Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices
Prasad, V., & Ioannidis, J. P. (2014) · Implementation Science · doi:10.1186/1748-5908-9-1 · Cited by 723
Metadata
- Authors
- Gøtzsche, P. C., & Nielsen, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2011-01-19
- Issue
- 1
- Pages
- CD001877-CD001877
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4211080020
- Cited by
- 311
- References
- 120
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for breast cancer with mammography. https://app.cochat.ai/papers/10.1002/14651858.cd001877.pub4
- The paper
- Gøtzsche, P. C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001877.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.